研發體系手機端標題
Adhering to the development path of industry university research, relying on the technical advantages of famous scientific research institutes such as the Chinese Academy of traditional Chinese medicine, Beijing University of traditional Chinese medicine and the Central Research Institute of the group, the company continued to carry out the development of new varieties of traditional Chinese medicine and the secondary development of famous and high-quality Chinese patent medicines, realized the organic combination of independent research and development and cooperative research, and formed Xinhuang Tablets, babaodan, Shenshu granules A group of compound Chinese patent medicines represented by Qigu capsule have independent intellectual property rights and major market prospects at home and abroad.
In recent years, the company has undertaken a number of national, provincial and municipal major projects, has obtained 31 invention patents and 18 utility model patents. Among them, the project "Babaodan Capsule and related Technologies Research" (2019ZX9201005-002-005) was included in the 2019 major new drug development science and technology major project; The topic of "Research on Key common technologies of Traditional Chinese Medicine drying molding process Data Characterization - Mining - Regulation" (2023YFC3504501) was included in the national key research and development plan "Traditional Chinese Medicine Modernization" key project in 2023; "Osteoporosis drug Qigu Capsule clinical reevaluation after the market" was selected as the subject of Shanghai Scientific Research plan.
cc1
